{
  "docId": "019de074-ad31-7288-aa0c-b4a964d6a9af",
  "docSlug": "31aafddb38d645745d1c40d83b8ae135",
  "documentTitle": "ATAI | Investor Presentation Deck | 30 slides",
  "authorId": "atai",
  "authorName": "atai",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 30,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 14,
  "notes": "The table highlights DMX-1002's unique profile compared to standard Medication Assisted Therapy and Withdrawal Support.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ad31-7288-aa0c-b4a964d6a9af/29",
  "deckHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af",
  "deckJsonHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af.json",
  "deckAnchorHref": "/decks/019de074-ad31-7288-aa0c-b4a964d6a9af#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.2,
        "x": 0.05,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "DMX-1002 could potentially become a paradigm-shifting therapy for Opioid Use Disorder (OUD). Current standard of care for OUD is medication therapy, requiring opioid substitutes that carry significant side effects. Current strategies for withdrawal support have high rates of relapse",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "951f1586-529f-4e59-b6ac-0b3017f73dd3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.6,
        "x": 0.26,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: OUD = Opioid Use Disorder. Source: Publicly available information, including company websites and clinicaltrials.gov, GlobalData, Evaluate Pharma (both as of 2022). 1. Current Standard of Care. 2. Rarely used given high rates of relapse. Used primarily in institutional or penitentiary settings",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "65a241d7-ebe8-4b77-a083-b5fd72aa0e68",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.7,
        "x": 0.26,
        "y": 0.21
      },
      "kind": "table",
      "text": "Comparison matrix of DMX-1002 vs Methadone, Buprenorphine, Naltrexone, Clonidine, and Lofexidine across 4 therapeutic criteria.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "295b024d-2ff8-43a8-bcdd-70d924ef61cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.7,
        "x": 0.26,
        "y": 0.07
      },
      "kind": "title",
      "text": "DMX-1002 has the potential to become the first & best in-class treatment for OUD, minimizing risk of relapse",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7544b330-18bf-48d4-9dc4-405e805a1e4b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.05,
        "y": 0.12
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af1bb141-bef0-4de6-a85f-c93521b919cb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "08cbda86-97f0-412b-9c7b-318823c98d28",
      "evidence": "The slide uses a matrix to compare the subject product against competitors across specific criteria.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 30,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "8a640552-7d64-4f46-af4c-8041a39da251",
      "evidence": "The deck presents a clear and compelling vision for ATAI's mission and solution",
      "position": 1,
      "objective": "Present a compelling vision for ATAI's mission and solution",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}